Results 1 to 10 of about 2,218 (130)

Flucytosine and its clinical usage

Therapeutic Advances in Infectious Disease, 2023
Flucytosine is an antifungal agent first licensed in the 1970’s. However, its clinical value has long been overlooked and its availability across the globe is limited.
David W. Denning, Shamithra Sigera
exaly   +3 more sources

New Mechanisms of Flucytosine Resistance in C. glabrata Unveiled by a Chemogenomics Analysis in S. cerevisiae. [PDF]

PLoS ONE, 2015
5-Flucytosine is currently used as an antifungal drug in combination therapy, but fungal pathogens are rapidly able to develop resistance against this drug, compromising its therapeutic action. The understanding of the underlying resistance mechanisms is
Catarina Costa, Andreia Ponte, Pedro Pais, Rui Santos, Mafalda Cavalheiro, Takashi Yaguchi, Hiroji Chibana, Miguel Cacho Teixeira   +7 more
doaj   +2 more sources

Time to embrace access programmes for medicines: lessons from the South African flucytosine access programme [PDF]

International Journal of Infectious Diseases, 2020
Background: Cryptococcal meningitis (CM) is estimated to cause 181 000 deaths annually, with the majority occurring in Sub-Saharan Africa. Flucytosine is recommended by the World Health Organization as part of the treatment for CM.
Amir Shroufi, Nelesh P. Govender, Graeme Meintjes, John Black, Jeremy Nel, Mahomed-Yunus S. Moosa, Colin Menezes, Halima Dawood, Douglas Wilson, Laura Trivino Duran, Olawale Ajose, Richard A. Murphy, Thomas Harrison, Angela Loyse, Carol Ruffell, Gilles Van Cutsem   +15 more
doaj   +2 more sources

Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa [PDF]

BMC Health Services Research, 2021
Background Cryptococcal meningitis in HIV-infected patients in sub-Saharan Africa accounts for three-quarters of the global cases and 135,000 deaths per annum. Current treatment includes the use of fluconazole and amphotericin B.
Jacqui Miot, Trudy Leong, Simbarashe Takuva, Andrew Parrish, Halima Dawood   +4 more
doaj   +2 more sources

Factors Influencing the Nitrogen-Source Dependent Flucytosine Resistance in Cryptococcus Species

mBio, 2023
Flucytosine (5-FC) is an antifungal agent commonly used for treatment of cryptococcosis and several other systemic mycoses. In fungi, cytosine permease and cytosine deaminase are known major players in flucytosine resistance by regulating uptake and ...
Dong-Hoon Yang, Ami Khanal Lamichhane, Kyung J. Kwon-Chung, Yun C. Chang   +3 more
doaj   +1 more source

Clinical Profile of 24 AIDS Patients with Cryptococcal Meningitis in the HAART Era: A Report from an Infectious Diseases Tertiary Hospital in Western Romania

Diagnostics, 2021
Management of cryptococcal infections among patients suffering from acquired immunodeficiency syndrome (AIDS) represents a medical challenge. This retrospective study aims to describe the disease management and outcomes among 24 AIDS patients who ...
Iosif Marincu, Cosmin Citu, Iulia Vidican, Felix Bratosin, Mihai Mares, Oana Suciu, Stefan Frent, Adrian Vasile Bota, Madalina Timircan, Melania Lavinia Bratu, Mirela Loredana Grigoras   +10 more
doaj   +1 more source

Epidemiological and Clinical Characteristics, Antifungal Susceptibility, and MLST-Based Genetic Analysis of Cryptococcus Isolates in Southern Taiwan in 2013–2020

Journal of Fungi, 2022
Cryptococcal meningoencephalitis (CM) is a treatable condition, but it leads to excessive morbidity and mortality. We collected 115 non-duplicated Cryptococcus clinical isolates during 2013–2020 in southern Taiwan to perform antifungal susceptibility ...
Yi-Chun Chen, Shu-Fang Kuo, Shang-Yi Lin, Yin-Shiou Lin, Chen-Hsiang Lee   +4 more
doaj   +1 more source

Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs [version 2; peer review: 2 approved, 1 approved with reservations]

Wellcome Open Research, 2022
Introduction: Access to and the cost of induction treatment for cryptococcal meningitis (CM) is rapidly changing. The newly-announced price for flucytosine ($0.75 per 500 mg pill) and possibly lower prices for liposomal amphotericin B (AmB-L) create ...
Amir Shroufi, Radha Rajasingham, Bruce Larson, Joseph N. Jarvis, Rita Oladele, Charles Muthoga, Tom M. Chiller, Alexander Jordan, Nelesh P. Govender   +8 more
doaj   +1 more source

Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans

Microbiology Spectrum, 2021
The high morbidity and mortality of cryptococcal meningitis is due to the limited range of therapeutic options: only three classes of antifungal drugs are available (polyenes [amphotericin B], azoles [fluconazole], and pyrimidine analogues [flucytosine]).
Feng Yang, Vladimir Gritsenko, Hui Lu, Cheng Zhen, Lu Gao, Judith Berman, Yuan-ying Jiang   +6 more
doaj   +1 more source

Prevalence of cryptococcal meningitis among people living with human immuno-deficiency virus and predictors of mortality in adults on induction therapy in Africa: A systematic review and meta-analysis

Frontiers in Medicine, 2022
BackgroundCryptococcal meningitis (CM) is a leading cause of adult meningitis in countries with a high burden of HIV. It has remained a significant cause of morbidity and mortality in Africa despite the extensive rollout of HIV antiretroviral therapy ...
Seke G. Y. Muzazu, Seke G. Y. Muzazu, Dawit Getachew Assefa, Dawit Getachew Assefa, Christabel Phiri, Tewodros Getinet, Samrawit Solomon, Gizachew Yismaw, Tsegahun Manyazewal   +8 more
doaj   +1 more source